Request an invite
Atlas/Cell therapy/Holoclar/Skipped studies

Holoclar: genotox, carcinogenicity and repro: done or skipped?

autologous corneal epithelial cells containing limbal stem cells · Autologous limbal stem cells
Check my plan vs. these
Genotoxicity
Not conducted (classical); in vitro karyotype analysis of cells
“The analysis demonstrated a consistent karyotypic profile throughout the tested cell cultures.”
✓ VerifiedEMA assessment report, p. 18Source ↗
Carcinogenicity
Not conducted (conventional); in vitro tumorigenicity assays instead
“While conventional carcinogenicity studies have not been performed, the potential for transformation and formation of tumours by the human corneal epithelial cells in Holoclar was investigated in in vitro assays.”
✓ VerifiedEMA assessment report, p. 18Source ↗
Reproductive & developmental
Not conducted; no systemic exposure and autologous product
“As no systemic exposure was to be expected and since the product was autologous in nature, the risk for product-related toxicity to the reproductive system was considered to be negligible”
✓ VerifiedEMA assessment report, p. 21Source ↗
Safety pharmacology
Not conducted; local ocular administration
“conventional pharmacodynamic safety and drug interactions studies were not conducted.”
✓ VerifiedEMA assessment report, p. 17Source ↗

Same question, other cell therapies

Abecma

idecabtagene vicleucel · BCMA CAR-T
Not conducted (traditional); insertion site analysis of 20 clinical lots

Alofisel

darvadstrocel · Allogeneic adipose MSC
Not conducted; cell-based product does not interact with DNA

Amtagvi

lifileucel · TIL therapy
Not conducted (not warranted given product characteristics and biological activity)

Aucatzyl

obecabtagene autoleucel · CD19 CAR-T
Not conducted (third-generation SIN lentiviral vector, release criterion, long-term clinical monitoring for insertional mutagenesis)

Breyanzi

lisocabtagene maraleucel · CD19 CAR-T
Not conducted (traditional); lentiviral integration site mapping instead

Carvykti

ciltacabtagene autoleucel · BCMA CAR-T
Not conducted (classical); lentiviral integration site analysis instead

ChondroCelect

characterised viable autologous cartilage cells · Autologous chondrocytes
Not conducted (per cell-based product guideline)

Ebvallo

tabelecleucel · EBV-specific allogeneic T cells
Not conducted (ICH S6(R1)); non-genetically engineered cells

Encelto

revakinagene taroretcel · CNTF (encapsulated RPE cell implant)
Done: ISO-10993 battery (bacterial, mammalian cell, mouse micronucleus on device extracts), negative

Gintuit

allogeneic cultured keratinocytes and fibroblasts in bovine collagen · Allogeneic keratinocytes + fibroblasts
Not conducted (nature of product and clinical experience)

Kymriah

tisagenlecleucel · CD19 CAR-T
Not conducted (classical); lentiviral integration site analysis on 14 donor products

Lantidra

donislecel · Allogeneic pancreatic islets
Not conducted

Laviv

azficel-T · Autologous fibroblasts
Not conducted (autologous nature, prior human experience)

MACI

autologous cultured chondrocytes on porcine collagen membrane · Autologous chondrocytes
Not conducted on cells; four studies on collagen membrane were non-mutagenic

Omisirge

omidubicel · Expanded cord blood HPC
No standard genotox; cytogenetic/karyotype analyses of CF and NF showed no clonal aneuploidy

Provenge

sipuleucel-T · PAP-GM-CSF (autologous APC)
Not conducted (autologous nature of product)

Rethymic

allogeneic processed thymus tissue · Allogeneic thymus tissue
Not conducted

Ryoncil

remestemcel-L · Allogeneic BM-MSC
Not conducted (not warranted)

Spherox

spheroids of autologous matrix-associated chondrocytes · Autologous chondrocyte spheroids
Not conducted (per cell-based product guideline)

StrataGraft

allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen · Allogeneic keratinocytes + fibroblasts
Not conducted

Tecartus

brexucabtagene autoleucel · CD19 CAR-T
Not conducted (traditional); vector integration site analysis performed instead

Tecelra

afamitresgene autoleucel · MAGE-A4 TCR-T
Not conducted (no test models or relevant species); integration site analysis showed polyclonal products, no selective insertion

Tregzi

allogeneic Treg immunotherapy with HSPC and T cells (Orca-T) · Allogeneic Treg + HSPC + Tcon
Not conducted

Yescarta

axicabtagene ciloleucel · CD19 CAR-T
Not conducted; literature review of retroviral-transduced T-cell transformation risk instead

Zalmoxis

allogeneic T cells modified with HSV-TK / dLNGFR (nalotimagene carmaleucel) · HSV-TK suicide-gene T cells
Not conducted; in vitro retroviral integration site analysis instead

Zemcelpro

dorocubicel · UM171-expanded cord blood CD34+
Done for residual UM171 only (Ames, CHO micronucleus negative) plus cytogenetics of treated cells; none for cells

Summary across all 27 cell therapies →